New Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Breast Cancer

What we are studying

The purpose of this study is to compare the addition of a new drug after the usual care of chemotherapy, surgery, and radiation for this type of cancer. In this study, you will get either the study drug or placebo, a pill that looks like the study drug but contains no medication. The use of the study drug could reduce the risk of your cancer coming back but it could also cause side effects. The study drug is experimental and not approved by the Food and Drug Administration (FDA) for use in any type of cancer.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Invasive breast cancer
  • Triple negative status (ER; PR; and HER2 negative)
  • BRCA1 or BRCA2 mutation

What is involved

  • Oral study drug or placebo for 12 months
  • Blood tests
  • Quality of Life Surveys (optional)

Compensation

None

Contact Information

Study Coordinator
Stacey Lewis
Email
stalewis@wakehealth.edu
Phone
336-713-6927

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.